Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.63 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.60 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.54 |
| ▸ | PPARG | P37231 | 7/20 | 0.54 |
| ▸ | PPARD | Q03181 | 7/20 | 0.54 |
| ▸ | PPARA | Q07869 | 7/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | FABP4 | P15090 | 2/20 | 0.54 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.54 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889830 | 1.00 | KDM4A (0.63) | KDM4AKDM4CADRA1ATSHRLMNA | |
| SCHEMBL8389930 | 1.00 | KDM4A (0.63) | KDM4AKDM4CADRA1ATSHRLMNA | |
| SCHEMBL5050892 | 1.00 | KDM4A (0.63) | KDM4AKDM4CADRA1ATSHRLMNA | |
| SCHEMBL28786185 | 1.00 | KDM4A (0.63) | KDM4AKDM4CADRA1ATSHRLMNA | |
| SCHEMBL8039895 | 1.00 | KDM4A (0.63) | KDM4AKDM4CADRA1ATSHRLMNA | |
| SCHEMBL6047707 | 1.00 | KDM4A (0.63) | KDM4AKDM4CADRA1ATSHRLMNA | |
| SCHEMBL17942985 | 1.00 | KDM4A (0.63) | KDM4AKDM4CADRA1ATSHRLMNA | |
| Hydrochloric Acid SCHEMBL3484697 | 0.98 | KDM4A (0.67) | KDM4AKDM4CADRA1ATSHRLMNA | |
| Hydrochloric Acid SCHEMBL4405208 | 0.98 | KDM4A (0.67) | KDM4AKDM4CADRA1ATSHRLMNA | |
| SCHEMBL693740 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186888-A1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| WO-2021202600-A1 | SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-10-07 | — | — | WO | disclosed |
| CN-110520409-A | Compounds and compositions for intracellular delivery of therapeutic agents | MODERNATX INC | 2019-11-29 | — | — | CN | disclosed |
| US-9840534-B2 | Process for the manufacture of cyclic undecapeptides | NOVARTIS AG (CH) | 2017-12-12 | — | — | US | disclosed |
| US-9770398-B2 | pH-sensitive compound, use, composition and treatment process using same | L'OREAL (FR) | 2017-09-26 | — | — | US | disclosed |
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20170097567-A1 | METHOD FOR PRODUCING POLYMER | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-04-06 | — | — | US | disclosed |
| US-20160304554-A1 | PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES | NOVARTIS PHARMA AG (CH) | 2016-10-20 | — | — | US | disclosed |
| US-20160229940-A1 | POLYMER, RESIST COMPOSITION, AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20150087808-A1 | PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES | NOVARTIS AG (CH) | 2015-03-26 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2415765-A1 | PYRIMIDINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| WO-2010113834-A1 | PYRIMIDINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-07 | — | — | WO | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20100016229-A1 | Oral GLP-1 Formulations | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2010-01-21 | — | — | US | disclosed |
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | KDM4A 196/4885KDM4C 646/4885ADRA1A 221/4885 |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | CNR2, CNR1, P2RY2 | KDM4A 2786/4885KDM4C 2644/4885ADRA1A 530/4885 |
| US-20150087808-A1 | PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES | UMPS, SAMHD1, NPEPPS | KDM4A 2047/4885KDM4C 3066/4885ADRA1A 4571/4885 |
| US-20160304554-A1 | PROCESS FOR THE MANUFACTURE OF CYCLIC UNDECAPEPTIDES | UMPS, SAMHD1, NPEPPS | KDM4A 2047/4885KDM4C 3066/4885ADRA1A 4571/4885 |
| US-20100016229-A1 | Oral GLP-1 Formulations | GLP1R, GIPR, GCGR | KDM4A 2468/4885KDM4C 2726/4885ADRA1A 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.